Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 24 | 2017 | 862 | 2.070 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2015 | 213 | 0.540 |
Why?
|
| Extracorporeal Membrane Oxygenation | 7 | 2016 | 616 | 0.510 |
Why?
|
| Graft Rejection | 5 | 2012 | 590 | 0.510 |
Why?
|
| Heart-Assist Devices | 9 | 2016 | 1026 | 0.430 |
Why?
|
| Azygos Vein | 2 | 2013 | 8 | 0.400 |
Why?
|
| Down Syndrome | 1 | 2015 | 198 | 0.400 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 537 | 0.320 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 313 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1251 | 0.300 |
Why?
|
| Peptide Fragments | 1 | 2012 | 781 | 0.290 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2007 | 20 | 0.280 |
Why?
|
| Bone Density | 1 | 2009 | 319 | 0.270 |
Why?
|
| Child, Preschool | 22 | 2017 | 14030 | 0.270 |
Why?
|
| Tissue Donors | 2 | 2012 | 494 | 0.250 |
Why?
|
| HLA Antigens | 3 | 2013 | 245 | 0.250 |
Why?
|
| Heart Failure | 7 | 2017 | 2299 | 0.240 |
Why?
|
| Infant | 21 | 2017 | 12518 | 0.240 |
Why?
|
| Heart Defects, Congenital | 4 | 2017 | 1827 | 0.230 |
Why?
|
| Renal Insufficiency | 1 | 2007 | 239 | 0.220 |
Why?
|
| Child | 27 | 2020 | 24436 | 0.220 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2004 | 118 | 0.200 |
Why?
|
| Isoantibodies | 2 | 2013 | 72 | 0.200 |
Why?
|
| Retrospective Studies | 18 | 2017 | 16389 | 0.190 |
Why?
|
| Stents | 1 | 2007 | 889 | 0.180 |
Why?
|
| Tissue and Organ Procurement | 1 | 2004 | 224 | 0.180 |
Why?
|
| Hospice Care | 1 | 2020 | 31 | 0.170 |
Why?
|
| Home Care Services | 1 | 2020 | 74 | 0.160 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 805 | 0.160 |
Why?
|
| Terminal Care | 1 | 2020 | 112 | 0.150 |
Why?
|
| Arkansas | 5 | 2012 | 58 | 0.150 |
Why?
|
| Heart Diseases | 3 | 2012 | 495 | 0.130 |
Why?
|
| Alkaline Phosphatase | 1 | 2017 | 98 | 0.130 |
Why?
|
| Adolescent | 16 | 2016 | 19373 | 0.130 |
Why?
|
| Humans | 31 | 2020 | 125392 | 0.130 |
Why?
|
| Infant, Newborn | 7 | 2016 | 8240 | 0.130 |
Why?
|
| Female | 22 | 2017 | 66885 | 0.130 |
Why?
|
| Waiting Lists | 2 | 2016 | 228 | 0.130 |
Why?
|
| Male | 22 | 2017 | 61663 | 0.120 |
Why?
|
| Odds Ratio | 3 | 2012 | 1260 | 0.110 |
Why?
|
| Respiration, Artificial | 2 | 2015 | 473 | 0.110 |
Why?
|
| Age of Onset | 1 | 2015 | 595 | 0.110 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 84 | 0.110 |
Why?
|
| Risk Factors | 7 | 2016 | 10331 | 0.110 |
Why?
|
| Vena Cava, Inferior | 1 | 2013 | 103 | 0.100 |
Why?
|
| Parvovirus B19, Human | 1 | 2012 | 30 | 0.100 |
Why?
|
| Parvoviridae Infections | 1 | 2012 | 36 | 0.100 |
Why?
|
| Dexmedetomidine | 1 | 2012 | 49 | 0.100 |
Why?
|
| Time Factors | 7 | 2015 | 6345 | 0.100 |
Why?
|
| Proteasome Inhibitors | 1 | 2012 | 60 | 0.100 |
Why?
|
| Boronic Acids | 1 | 2012 | 46 | 0.100 |
Why?
|
| Ventricular Function | 1 | 2012 | 91 | 0.090 |
Why?
|
| Treatment Outcome | 11 | 2015 | 12412 | 0.090 |
Why?
|
| Pyrazines | 1 | 2012 | 73 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2012 | 5185 | 0.090 |
Why?
|
| Hypnotics and Sedatives | 1 | 2012 | 133 | 0.090 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2012 | 240 | 0.090 |
Why?
|
| Lipocalins | 1 | 2011 | 30 | 0.090 |
Why?
|
| Acute-Phase Proteins | 1 | 2011 | 47 | 0.090 |
Why?
|
| Myocarditis | 1 | 2012 | 129 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2012 | 480 | 0.090 |
Why?
|
| Cystatin C | 1 | 2011 | 58 | 0.090 |
Why?
|
| Catheters | 1 | 2011 | 86 | 0.090 |
Why?
|
| Ductus Arteriosus | 1 | 2011 | 62 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2011 | 152 | 0.090 |
Why?
|
| Heparin | 2 | 2008 | 224 | 0.080 |
Why?
|
| Logistic Models | 2 | 2012 | 1815 | 0.080 |
Why?
|
| Echocardiography, Doppler | 1 | 2010 | 171 | 0.080 |
Why?
|
| Catheterization | 1 | 2011 | 235 | 0.080 |
Why?
|
| Biomarkers | 3 | 2017 | 3096 | 0.080 |
Why?
|
| Norwood Procedures | 1 | 2010 | 101 | 0.080 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 178 | 0.080 |
Why?
|
| Cardiac Catheterization | 2 | 2010 | 634 | 0.080 |
Why?
|
| Pipecolic Acids | 1 | 2008 | 7 | 0.080 |
Why?
|
| Oxygen | 1 | 2012 | 557 | 0.080 |
Why?
|
| Drug-Eluting Stents | 1 | 2008 | 64 | 0.070 |
Why?
|
| Heart Septum | 1 | 2008 | 54 | 0.070 |
Why?
|
| Fontan Procedure | 1 | 2010 | 182 | 0.070 |
Why?
|
| Transplantation | 1 | 2008 | 27 | 0.070 |
Why?
|
| Tricuspid Valve | 1 | 2008 | 60 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 547 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 43 | 0.070 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2008 | 180 | 0.070 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2010 | 257 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2009 | 188 | 0.070 |
Why?
|
| Histocompatibility Testing | 1 | 2007 | 148 | 0.070 |
Why?
|
| Angiography | 1 | 2007 | 216 | 0.070 |
Why?
|
| Anticoagulants | 2 | 2008 | 594 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 226 | 0.070 |
Why?
|
| Body Weight | 1 | 2010 | 989 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 305 | 0.060 |
Why?
|
| Echocardiography | 1 | 2011 | 1057 | 0.060 |
Why?
|
| Cardiology | 1 | 2011 | 507 | 0.060 |
Why?
|
| Oximetry | 1 | 2007 | 171 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2008 | 683 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2008 | 678 | 0.060 |
Why?
|
| Kidney | 1 | 2011 | 1369 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 1104 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2007 | 454 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2007 | 463 | 0.050 |
Why?
|
| Palliative Care | 2 | 2020 | 434 | 0.050 |
Why?
|
| Hospitals, Pediatric | 1 | 2006 | 764 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2014 | 3306 | 0.040 |
Why?
|
| Prevalence | 1 | 2007 | 2467 | 0.040 |
Why?
|
| Terminally Ill | 1 | 2020 | 28 | 0.040 |
Why?
|
| Reoperation | 2 | 2014 | 833 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2016 | 1506 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 2176 | 0.040 |
Why?
|
| Graft Survival | 2 | 2012 | 538 | 0.040 |
Why?
|
| Warfarin | 2 | 2008 | 119 | 0.030 |
Why?
|
| Child Welfare | 2 | 2008 | 64 | 0.030 |
Why?
|
| Young Adult | 1 | 2009 | 9069 | 0.030 |
Why?
|
| Critical Care | 1 | 2020 | 658 | 0.030 |
Why?
|
| Sternotomy | 1 | 2014 | 42 | 0.030 |
Why?
|
| Length of Stay | 2 | 2010 | 1312 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 2014 | 103 | 0.030 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2015 | 163 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2010 | 6168 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 2013 | 216 | 0.030 |
Why?
|
| Age Factors | 2 | 2010 | 2827 | 0.020 |
Why?
|
| Bortezomib | 1 | 2012 | 70 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 1186 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 435 | 0.020 |
Why?
|
| Morbidity | 1 | 2012 | 249 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2011 | 75 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 359 | 0.020 |
Why?
|
| Lipocalin-2 | 1 | 2011 | 29 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 590 | 0.020 |
Why?
|
| Pulmonary Valve | 1 | 2012 | 92 | 0.020 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2010 | 17 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2010 | 50 | 0.020 |
Why?
|
| Ventricular Pressure | 1 | 2010 | 41 | 0.020 |
Why?
|
| Tetralogy of Fallot | 1 | 2012 | 164 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2010 | 112 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 2012 | 168 | 0.020 |
Why?
|
| Ventricular Function, Right | 1 | 2010 | 112 | 0.020 |
Why?
|
| Heparin Antagonists | 1 | 2008 | 5 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 571 | 0.020 |
Why?
|
| Mitral Valve | 1 | 2010 | 250 | 0.020 |
Why?
|
| Protamines | 1 | 2008 | 13 | 0.020 |
Why?
|
| Dipyridamole | 1 | 2008 | 28 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 1586 | 0.020 |
Why?
|
| Antithrombin III | 1 | 2008 | 25 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2008 | 23 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2008 | 42 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 1020 | 0.020 |
Why?
|
| Thrombin | 1 | 2008 | 61 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 446 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 507 | 0.020 |
Why?
|
| Patient Safety | 1 | 2012 | 401 | 0.020 |
Why?
|
| North America | 1 | 2008 | 242 | 0.020 |
Why?
|
| Energy Intake | 1 | 2010 | 494 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2008 | 257 | 0.020 |
Why?
|
| Heart | 1 | 2012 | 730 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 2062 | 0.020 |
Why?
|
| Myocardium | 1 | 2012 | 1021 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 555 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2012 | 978 | 0.020 |
Why?
|
| Biopsy | 1 | 2010 | 1240 | 0.020 |
Why?
|
| Aspirin | 1 | 2008 | 221 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2008 | 271 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2008 | 301 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2008 | 450 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2008 | 270 | 0.020 |
Why?
|
| Arginine | 1 | 2008 | 336 | 0.020 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2007 | 145 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2007 | 334 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 473 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 1058 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 4824 | 0.010 |
Why?
|
| Texas | 1 | 2012 | 3589 | 0.010 |
Why?
|
| Infant Welfare | 1 | 2003 | 28 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1039 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 880 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2008 | 941 | 0.010 |
Why?
|
| Adult | 3 | 2012 | 29692 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 4648 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2003 | 772 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2003 | 499 | 0.010 |
Why?
|
| Aged | 1 | 2012 | 19896 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2003 | 3075 | 0.010 |
Why?
|